Table 3.
Study type | Subjects | Administration methods | Dose & duration | Effects and mechanisms | Ref. |
---|---|---|---|---|---|
The suppression of oxidative stress | |||||
In vitro | Human erythrocytes | Cell culture | 0.1–100 μM | Activated the plasma membrane redox system and ascorbate-free radical reductase, protected against lipid peroxidation and protein carbonylation, and restored the cellular redox homeostasis | [78] |
In vitro | Immortalized lymphocytes | Cell culture | 10 and 50 μM | Reduced the generation of ROS, upregulated the gene expression of antioxidants and antiaging factors | [79] |
In vivo | F2 four-way cross-hybrid mice | Drinking water | 14.09 mg/L for 6 or 12 months | Reversed oxidative damage but might result in nephrotoxicity | [80] |
In vivo | Male grey mouse lemur | Diet supplement | 200 mg/kg for 3-21 months | Ameliorated oxidative stress with age increase | [81] |
In vivo | Male C57BL/6J mice | Drinking water | 500 μg/animal for 6 months | Retarded the impact of aging and sustained high activities of GSH, GPx, and GSH transferase activities | [82] |
In vivo | Male Wistar rats | Oral administration | 10 mg/kg for 2-8 months | Decreased the level of NO and retarded the lipoperoxidation in the cardiac tissue | [83] |
In vivo | C57BL/6 mice | Diet supplement | 0.05% for 10 days | Blunted the exercise-induced increase in xanthine oxidase activity in muscles, lower H2O2, and Nox4 protein levels, increased the ratio of reduced GSH to oxidized GSH, prevented the increase in lipid oxidation, increased CAT and SOD activities | [112] |
In vivo | Young and aged rats | Perfusion | NA | Ameliorated H2O2-induced oxidative stimulus in both young and aged rat brains and ameliorated basal oxidative stress in aged rat brains | [113] |
In vivo | Aged C57BL/6 mice | Oral administration | 30 mg/kg | Ameliorating renal oxidative stress via the Sirt1-mediated klotho expression | [114] |
The inhibition of inflammation | |||||
In vitro | Vascular smooth muscle cells | Cell culture | 1 μM | Reduced the secretion of IL-1β, IL-8, TNF-α, and MCP-1, decreased the production of O2·- in mitochondria, and upregulated the transcriptional activity of Nrf2 | [86] |
In vitro | Hippocampal astrocyte | Cell culture | 10 μM | Decreased proinflammatory cytokines IL-1β and TNF-α and increased antioxidant defenses | [87] |
In vivo | Male BALB/c mice | Diet supplement | 0.4% for 4 weeks | Mitigated inflammatory response and cognitive deficits and reduced the increase of IL-1β in plasma and the IL-1β mRNA in the hippocampus | [88] |
In vivo | Female C57BL/6 mice | Diet supplement | 4 g/kg for 12 months | Reduced age-associated inflammation independently of PGC-1α | [89] |
In vivo | Aged female mice | Oral gavage | 0.1 mg/kg for 10 days | Attenuated peripheral and brain inflammation and ischemic brain injury | [115] |
In vivo | Male C57BL/6J mice | Diet supplement | 1 g/kg, W/W | Reduced the inflammation and cognitive disturbances induced by metabolic stress | [90] |
The improvement of mitochondrial function | |||||
In vitro | Oocytes and granulosa cells | Cell culture | 20 μM | Affected both oocytes and granulosa and improved the quality of oocytes through upregulation of mitochondrial biogenesis and degradation | [94] |
In vivo | Aged mice | Oral gavage | 15 mg/kg for 4 weeks | Improved physical endurance and oxidative stress via the regulation of mitochondrial biogenesis and function | [50] |
In vivo | Female ICR mice | Intraperitoneal injection | 50 mg/kg BW | Improved mitochondrial function, alleviated oxidative stress, and prevented apoptosis | [95] |
In vivo | Aged zebrafish | Administration | 20 mg/L | Promoted mitochondrial function and downregulated Akt/mTOR pathway activity | [17] |
The regulation of apoptosis | |||||
In vivo | Aged Sprague-Dawley rats | Intraperitoneal injection | 100 mg/kg for 7 days | Modified the performance of learning and memory, suppressed neuronal apoptosis | [67] |
In vivo | Aged senescence-accelerated mice | Drinking water | 5 mg/kg | Modulated the inflammatory, oxidative, and apoptotic status related to aging | [16] |
In vivo, in vitro | Male albino Wistar rats; human diploid fibroblast strain | Oral administration | 50, 100 mg/kg | Displayed antiaging activities by inhibiting senescence and apoptosis and recovering cognitive impairment and oxidative damage | [98] |
In vitro | Mouse neuronal N2a cells | Cell culture | 1.5 to 25 μM | Counteracted apoptosis, autophagy, and oxidative stress, associated with mitochondrial and peroxisomal dysfunction induced by 7-Ketocholesterol | [116] |
In vivo | Sprague-Dawley rats | Oral gavage | 80 mg/kg | Decreased apoptotic index, improved mitochondrial function, and inhibited oxidative stress | [99] |
In vivo | Senescence-accelerated mice | Diet supplement | 4.9 mg/kg for 8 months | Improved exercise capacity and voluntary motor behavior, increased the protein expression of antiapoptotic Bcl2 | [100] |
In vivo | Male senescence-accelerated mice | Intraperitoneal injection | 20 mg/kg/day for 3 days | Attenuated the doxorubicin-induced elevations of apoptotic and catabolic markers measured as Bax, caspase 3 activity, apoptotic DNA fragmentation, ubiquitinated proteins, and proteasomal activity in aged muscles | [117] |
Note: ROS: reactive oxygen species; GSH: glutathione; GPx: glutathione peroxidase; NO: nitric oxide; Nox4: NADPH oxidase 4; CAT: catalase; SOD: superoxide dismutase; Sirt1: sirtuin1; IL: interleukin; TNF-α: tumor necrosis factor-α; MCP-1: monocyte chemoattractant protein-1; Nrf2: nuclear factor erythroid-2 related factor 2; PGC-1α: peroxisome proliferator-activated receptor-γ coactivator-1α; Bcl2: B-cell lymphoma-2; Bax: BCL2-associated X.